Administration of RIP‐12 inhibited the growth of IMR‐32 cell‐derived xenograft tumors, as evidenced by reduction in tumor volume, weight, and Ki‐67 proliferative activity (Figure 6E; Figure S11E, Supporting Information), along with up‐regulation of NR1D1, RIOK3, FLCN, or FNIP1 as well as down‐regulation of LAMP1 (Figure S11F, Supporting Information). Here, LAMP1 is linked to neoplasm.